|
1
|
Schwab M: MYCN in neuronal tumours.
Cancer Lett. 204:179–187. 2004. View Article : Google Scholar
|
|
2
|
Kyo Y, Tanaka T, Hayashi K, et al:
Identification of therapy-sensitive and therapy-resistant
neuroblastoma subtypes in stages III, IVs and IV. Cancer Lett.
306:27–33. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Evan GI and Vousden KH: Proliferation,
cell cycle and apoptosis in cancer. Nature. 411:342–348. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Westermark UK, Wilhelm M, Frenzel A and
Henriksson MA: The MYCN oncogene and differentiation in
neuroblastoma. Semin Cancer Biol. 21:256–266. 2011.
|
|
5
|
Souzaki R, Tajiri T, Teshiba R, et al: The
genetic and clinical significance of MYCN gain as detected by FISH
in neuroblastoma. Pediatr Surg Int. 27:231–236. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ambros PF, Ambros IM, Brodeur GM, et al:
International consensus for neuroblastoma molecular diagnostics:
report from the International Neuroblastoma Risk Group (INRG)
Biology Committee. Br J Cancer. 100:1471–1482. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Prochazka P, Hrabeta J, Vicha A and
Eckschlager T: Expulsion of amplified MYCN from homogenously
staining chromosomal regions in neuroblastoma cell lines after
cultivation with cisplatin, doxorubicin, hydroxyurea, and
vincristine. Cancer Genet Cytogenet. 196:96–104. 2010. View Article : Google Scholar
|
|
8
|
Baumann Kubetzko FB, Di Paolo C, Maag C,
et al: The PAX5 oncogene is expressed in N-type neuroblastoma cells
and increases tumorigenicity of a S-type cell line. Carcinogenesis.
25:1839–1846. 2004.PubMed/NCBI
|
|
9
|
Bian X, Giordano TD, Lin HJ, Solomon G,
Castle VP and Opipari AW Jr: Chemotherapy-induced apoptosis of
S-type neuroblastoma cells requires caspase-9 and is augmented by
CD95/Fas stimulation. J Biol Chem. 279:4663–4669. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Maris JM, Hogarty MD, Bagatell R and Cohn
SL: Neuroblastoma. Lancet. 369:2106–2120. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
de Cremoux P, Jourdan-Da-Silva N,
Couturier J, et al: Role of chemotherapy resistance genes in
outcome of neuroblastoma. Pediatr Blood Cancer. 48:311–317.
2007.
|
|
12
|
Brodeur GM: Neuroblastoma: biological
insights into a clinical enigma. Nat Rev Cancer. 3:203–216. 2003.
View Article : Google Scholar
|
|
13
|
Tang XX, Zhao H, Kung B, et al: The
MYCN enigma: significance of MYCN expression in
neuroblastoma. Cancer Res. 66:2826–2833. 2006.
|
|
14
|
Lutz W and Schwab M: In vivo regulation of
single copy and amplified N-myc in human neuroblastoma
cells. Oncogene. 15:303–315. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Westermann F, Muth D, Benner A, et al:
Distinct transcriptional MYCN/c-MYC activities are associated with
spontaneous regression or malignant progression in neuroblastomas.
Genome Biol. 9:R1502008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fulda S, Lutz W, Schwab M and Debatin KM:
MycN sensitizes neuroblastoma cells for drug-induced apoptosis.
Oncogene. 18:1479–1486. 1999.
|
|
17
|
Porro A, Haber M, Diolaiti D, et al:
Direct and coordinate regulation of ATP-binding cassette
transporter genes by Myc factors generates specific transcription
signatures that significantly affect the chemoresistance phenotype
of cancer cells. J Biol Chem. 285:19532–19543. 2010. View Article : Google Scholar
|
|
18
|
Bell E, Chen L, Liu T, Marshall GM, Lunec
J and Tweddle DA: MYCN oncoprotein targets and their therapeutic
potential. Cancer Lett. 293:144–157. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Albihn A, Johnsen JI and Henriksson MA:
MYC in oncogenesis and as a target for cancer therapies. Adv Cancer
Res. 107:163–224. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gustafson WC and Weiss WA: Myc proteins as
therapeutic targets. Oncogene. 29:1249–1259. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Prochazka P, Libra A, Zemanova Z, et al:
Mechanisms of ellipticine-mediated resistance in UKF-NB-4
neuroblastoma cells. Cancer Sci. 103:334–341. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kotchetkov R, Cinatl J, Blaheta R, et al:
Development of resistance to vincristine and doxorubicin in
neuroblastoma alters malignant properties and induces additional
karyotype changes: a preclinical model. Int J Cancer. 104:36–43.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Poljakova J, Eckschlager T, Hrabeta J, et
al: The mechanism of cytotoxicity and DNA adduct formation by the
anticancer drug ellipticine in human neuroblastoma cells. Biochem
Pharmacol. 77:1466–1479. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pfaffl MW, Horgan GW and Dempfle L:
Relative expression software tool (REST) for group-wise comparison
and statistical analysis of relative expression results in
real-time PCR. Nucleic Acids Res. 30:e362002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bordow SB, Haber M, Madafiglio J, Cheung
B, Marshall GM and Norris MD: Expression of the multidrug
resistance-associated protein (MRP) gene correlates with
amplification and overexpression of the N-myc oncogene in childhood
neuroblastoma. Cancer Res. 54:5036–5040. 1994.
|
|
26
|
Beiske K, Ambros PF, Burchill SA, Cheung
IY and Swerts K: Detecting minimal residual disease in
neuroblastoma patients - the present state of the art. Cancer Lett.
228:229–240. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hogarty MD, Norris MD, Davis K, et al:
ODC1 is a critical determinant of MYCN oncogenesis
and a therapeutic target in neuroblastoma. Cancer Res.
68:9735–9745. 2008. View Article : Google Scholar
|
|
28
|
Ambros PF and Ambros IM; SIOP Europe
Neuroblastoma Pathology, Biology and Bone Marrow Group. Pathology
and biology guidelines for resectable and unresectable neuroblastic
tumors and bone marrow examination guidelines. Med Pediatr Oncol.
37:492–504. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Valent A, Le Roux G, Barrois M, et al:
MYCN gene overrepresentation detected in primary neuroblastoma
tumour cells without amplification. J Pathol. 198:495–501. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jeison M, Ash S, Halevy-Berko G, et al:
2p24 Gain region harboring MYCN gene compared with
MYCN amplified and nonamplified neuroblastoma: biological
and clinical characteristics. Am J Pathol. 176:2616–2625.
2010.PubMed/NCBI
|
|
31
|
Spitz R, Hero B, Skowron M, Ernestus K and
Berthold F: MYCN-status in neuroblastoma: characteristics of
tumours showing amplification, gain, and non-amplification. Eur J
Cancer. 40:2753–2759. 2004. View Article : Google Scholar
|
|
32
|
Cohen N, Betts DR, Rechavi G, Amariglio N
and Trakhtenbrot L: Clonal expansion and not cell interconversion
is the basis for the neuroblast and nonneuronal types of the
SK-N-SH neuroblastoma cell line. Cancer Genet Cytogenet. 143:80–84.
2003.PubMed/NCBI
|
|
33
|
Ambros IM, Brunner B, Aigner G, et al: A
multilocus technique for risk evaluation of patients with
neuroblastoma. Clin Cancer Res. 17:792–804. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chan HS, Gallie BL, DeBoer G, et al:
MYCN protein expression as a predictor of neuroblastoma
prognosis. Clin Cancer Res. 3:1699–1706. 1997.
|
|
35
|
Cohn SL, London WB, Huang D, et al: MYCN
expression is not prognostic of adverse outcome in advanced-stage
neuroblastoma with nonamplified MYCN. J Clin Oncol. 18:3604–3613.
2000.PubMed/NCBI
|
|
36
|
Bieche I, Laurendeau I, Tozlu S, et al:
Quantitation of MYC gene expression in sporadic breast
tumors with a real-time reverse transcription-PCR assay. Cancer
Res. 59:2759–2765. 1999.
|
|
37
|
Smith DR and Goh HS: Overexpression of the
c-myc proto-oncogene in colorectal carcinoma is associated with a
reduced mortality that is abrogated by point mutation of the p53
tumor suppressor gene. Clin Cancer Res. 2:1049–1053.
1996.PubMed/NCBI
|
|
38
|
Paffhausen T, Schwab M and Westermann F:
Targeted MYCN expression affects cytotoxic potential of
chemotherapeutic drugs in neuroblastoma cells. Cancer Lett.
250:17–24. 2007.
|
|
39
|
Bedrnicek J, Vicha A, Jarosova M, et al:
Characterization of drug-resistant neuroblastoma cell lines by
comparative genomic hybridization. Neoplasma. 52:415–419.
2005.PubMed/NCBI
|
|
40
|
van Noesel MM, Pieters R, Voute PA and
Versteeg R: The N-myc paradox: N-myc overexpression in
neuroblastomas is associated with sensitivity as well as resistance
to apoptosis. Cancer Lett. 197:165–172. 2003.PubMed/NCBI
|
|
41
|
Wasenius VM, Jekunen A, Monni O, et al:
Comparative genomic hybridization analysis of chromosomal changes
occurring during development of acquired resistance to cisplatin in
human ovarian carcinoma cells. Genes Chromosomes Cancer.
18:286–291. 1997. View Article : Google Scholar
|
|
42
|
Nara K, Kusafuka T, Yoneda A, Oue T,
Sangkhathat S and Fukuzawa M: Silencing of MYCN by RNA
interference induces growth inhibition, apoptotic activity and cell
differentiation in a neuroblastoma cell line with MYCN
amplification. Int J Oncol. 30:1189–1196. 2007.
|
